Clinical Trial Recruitment in Orphan Diseases - Patient Numbers in Ovarian Cancer Trials Exceed Other Orphan Diseases in Oncology

GBI Research, the leading business intelligence provider, has released its latest research, “Clinical Trial Recruitment in Orphan Diseases - Patient Numbers in Ovarian Cancer Trials Exceed Other Orphan Diseases in Oncology”. It gives a robust idea about the patient recruitment status by geography, by Sponsor Company and by year for all the major orphan diseases in CNS and oncology. The report also compares the clinical trials and patient recruitment in orphan diseases with other diseases in CNS and oncology. Furthermore, the report provides profiles of prevalence forecast data up to 2017 for all the major indications. The major indications covered in the report are Huntington’s disease, Amyotrophic Lateral Sclerosis (ALS), ovarian disease, pancreatic disease, Hodgkin’s lymphoma, multiple myeloma and Acute Myeloid Leukemia (AML). It is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts.

An orphan disease is not common and its occurrence is said to be rare. These diseases have a low rate of prevalence in the existing population and a physician rarely gets to see patients with these conditions. Most of the orphan diseases are often genetic and hence they persist throughout a person’s life. It is estimated that 80% of orphan diseases have genetic origins. The remaining occurs due to allergies, degenerative causes, proliferative causes and as a result of infection. The symptoms for these diseases are not immediate and it occurs late for most of the conditions. The definition of orphan diseases varies with geography and is primarily dependent upon the prevalence of a disease.

In the US, orphan diseases are those that affect fewer than 6.6 per 10,000 (Orphan drug Act 1983). The US National Organization for Rate Disorders (NORD) has more than 1,200 diseases in their list while National Institute of Health (NIH)’s office for rare diseases published a list of more than 6,000 disease disorders ranging from Aagenaes syndrome to Zuska’s Disease. In Europe, orphan diseases are those that have a prevalence of less than 5 per 10,000 of the population. According to European Organization for Rare Diseases (EURORDIS), there are about 6,000 to 8,000 orphan diseases that exist in Europe. In Japan, orphan diseases are those that have a prevalence of less then 4 per 10,000 (Orphan Drug Act 1993).

The regulatory bodies play a crucial role in defining the orphan diseases as well as providing incentives to manufacturers who are involved in development of orphan drugs. Before the approval of orphan drugs, every molecule is designated as an orphan drug and will enter clinical trials. It is approved as an orphan drug only after the molecule clears the various phases in a clinical trial.

Clinical trials are one of the most critical parts of the drug development process. The various aspects involved in clinical trials such as implementation of technology, efficient supply chain management, proper site selection, patient recruitment, database management and others are important. Clinical trial recruitment is a time consuming process therefore good strategies need to be followed by pharmaceutical companies for adequate patient recruitment.

Scope

- Insight on Clinical Trials conducted for major indications of cardiology such as Huntington’s disease, ALS, ovarian cancer, pancreatic cancer, Hodgkin’s lymphoma, multiple myeloma and AML from 2000 to 2010.

- The status of patient recruitment by geography, Sponsor Company, year and stage of development.

- The comparison of clinical trials and patient recruitment in orphan diseases with other diseases in CNS and oncology

- Analysis on the average number of patients recruited per trial for major indications per year.

- Analysis on the average number of patients recruited per trial for major indications by stage of development.

- The prevalence population in the US, Europe and Japan for all major indications from 2010-2017.

Reasons to buy

- Identify and understand the status of clinical trials conducted for major orphan diseases from 2000 to 2010.

- Build understanding of patient recruitment status by geography, sponsor company, year and stage of development.

- Identify the prevalence within a population for major indications till 2017.

- Identify the average number of patients recruited by stage of development and across years for all major indications and the comparison with other diseases.

- Identify the indication in which the maximum number of trials is conducted and maximum number of patients recruited.

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Clinical Trials in Orphan Diseases: Introduction
2.1 Disease Overview
2.1.1 The US
2.1.2 Europe
2.1.3 Japan
2.2 GBI Research Report Guidance

3 Clinical Trials and Patient Recruitment for Orphan Diseases in Central Nervous System(CNS)
3.1 Huntington’s disease
3.1.1 Introduction
3.1.2 Number of Clinical Trials for Huntington’s disease
3.1.3 Prevalence Population for Huntington’s disease (2010-2017)
3.1.4 Patient Recruitment for Huntington’s Disease
3.1.5 Average Number of Patients Recruited Per Trial
3.2 Amyotrophic Lateral Sclerosis (ALS)
3.2.1 Introduction
3.2.2 Number of Clinical Trials for Amyotrophic Lateral Sclerosis
3.2.3 Prevalence Population for ALS (2010-2017)
3.2.4 Patient Recruitment for Amyotrophic Lateral Sclerosis
3.2.5 Average Number of Patients Recruited Per Trial
3.3 Comparison of Clinical Trials and Patient Recruitment of Orphan Diseases with Other CNS Diseases
3.3.1 Number of Clinical Trials
3.3.2 Number of Patients Recruited
3.3.3 Average Number of Patients Recruited per Phase
3.3.4 Average Number of Patients Recruited per Year

4 Clinical Trials and Patient Recruitment for Orphan Diseases in Oncology
4.1 Ovarian Cancer
4.1.1 Introduction
4.1.2 Number of Clinical Trials for Ovarian Cancer
4.1.3 Prevalence Population for Ovarian Cancer (2010-2017)
4.1.4 Patient Recruitment for Ovarian Cancer
4.1.5 Average Number of Patients Recruited Per Trial
4.2 Pancreatic Cancer
4.2.1 Introduction
4.2.2 Number of Clinical Trials for Pancreatic Cancer
4.2.3 Prevalence Population for Pancreatic Cancer (2010-2017)
4.2.4 Patient Recruitment for Pancreatic cancer
4.2.5 Average Number of Patients Recruited Per Trial
4.3 Multiple Myeloma
4.3.1 Introduction
4.3.2 Number of Clinical Trials for Multiple Myeloma
4.3.3 Prevalence Population for Multiple Myeloma (2010-2017)
4.3.4 Patient Recruitment for Multiple Myeloma
4.3.5 Average Number of Patients Recruited Per Trial
4.4 Hodgkin’s Lymphoma
4.4.1 Introduction
4.4.2 Number of Clinical Trials for Hodgkin’s Lymphoma
4.4.3 Prevalence Population for Hodgkin’s Lymphoma (2010-2017)
4.4.4 Patient Recruitment for Hodgkin’s Lymphoma
4.4.5 Average Number of Patients Recruited Per Trial
4.5 Acute Myelocytic Leukemia (AML)
4.5.1 Introduction
4.5.2 Number of Clinical Trials for Acute Myelocytic Leukemia
4.5.3 Prevalence Population for Acute Myelocytic Leukemia (2010-2017)
4.5.4 Patient Recruitment for Multiple Myeloma
4.5.5 Average Number of Patients Recruited Per Trial
4.6 Comparison of Clinical Trials and Patient Recruitment of Orphan Diseases with Other Oncology Diseases
4.6.1 Number of Clinical Trials
4.6.2 Number of Patients Recruited
4.6.3 Average Number of Patients Recruited per Phase
4.6.4 Average Number of Patients Recruited per Year

5 Clinical Trial Recruitment in Orphan Diseases-Appendix
5.1 Market Definitions
5.2 Abbreviations
5.3 Research Methodology
5.3.1 Coverage
5.3.2 Secondary Research
5.3.3 Primary Research
5.3.4 Expert Panel Validation
5.3.5 Section-wise methodology
5.4 Contact Us
5.5 Disclaimer
5.6 Sources

1.1 List of Tables

Table 1: Clinical Trial Recruitment in Orphan Diseases, Huntington’s Disease, Total Number of Clinical Trials by Phase, 2000–2010
Table 2: Clinical Trial Recruitment in Orphan Diseases, Huntington’s Disease, Total Number of Clinical Trials by Major Sponsors, 2000–2010
Table 3: Clinical Trial Recruitment in Orphan Diseases, Huntington’s Disease, Total Number of Clinical Trials by Geography, 2000–2010
Table 4: Clinical Trial Recruitment in Orphan Diseases, Huntington’s Disease, Total Number of Clinical Trials by Year, 2000–2010
Table 5: Clinical Trial Recruitment in Orphan Diseases, Huntington’s Disease, The US, Prevalence Population, 2010–2017
Table 6: Clinical Trial Recruitment in Orphan Diseases, Huntington’s Disease, Europe, Prevalence Population, 2010–2017
Table 7: Clinical Trial Recruitment in Orphan Diseases, Huntington’s Disease, Japan, Prevalence Population, 2010–2017
Table 8: Clinical Trial Recruitment in Orphan Diseases, Huntington’s Disease, Total Number of Patients Recruited by Phase, 2000–2010
Table 9: Clinical Trial Recruitment in Orphan Diseases, Huntington’s Disease, Total Number of Patients Recruited by Major Sponsors, 2000–2010
Table 10: Clinical Trial Recruitment in Orphan Diseases, Huntington’s Disease, Total Number of Patients Recruited by Geography, 2000–2010
Table 11: Clinical Trial Recruitment in Orphan Diseases, Huntington’s Disease, Total Number of Patients Recruited by Year, 2000–2010
Table 12: Clinical Trial Recruitment in Orphan Diseases, Huntington’s Disease, Total, Average Number of Patients Recruited per Trial by Stage of Development, 2000–2010
Table 13: Clinical Trial Recruitment in Orphan Diseases, Huntington’s Disease, Total, Average Number of Patients Recruited per Trial per Year, 2000–2010
Table 14: Clinical Trial Recruitment in Orphan Diseases, ALS, Total Number of Clinical Trials by Phase, 2000–2010
Table 15: Clinical Trial Recruitment in Orphan Diseases, ALS, Total Number of Clinical Trials by Sponsor, 2000–2010
Table 16: Clinical Trial Recruitment in Orphan Diseases, ALS, Total Number of Clinical Trials by Geography, 2000–2010
Table 17: Clinical Trial Recruitment in Orphan Diseases, ALS, Total Number of Clinical Trials by Year, 2000–2010
Table 18: Clinical Trial Recruitment in Orphan Diseases, ALS, The US, Prevalence Population, 2010–2017
Table 19: Clinical Trial Recruitment in Orphan Diseases, ALS, Europe, Prevalence Population, 2010–2017
Table 20: Clinical Trial Recruitment in Orphan Diseases, ALS, Japan, Prevalence Population, 2010–2017
Table 21: Clinical Trial Recruitment in Orphan Diseases, ALS, Total Number of Patients Recruited by Phase, 2000–2010
Table 22: Clinical Trial Recruitment in Orphan Diseases, ALS, Total Number of Patients Recruited by Major Sponsors, 2000–2010
Table 23: Clinical Trial Recruitment in Orphan Diseases, ALS, Total Number of Patients Recruited by Geography, 2000–2010
Table 24: Clinical Trial Recruitment in Orphan Diseases, ALS, Total Number of Patients Recruited by Year, 2000–2010
Table 25: Clinical Trial Recruitment in Orphan Diseases, ALS, Average Number of Patients Recruited per Trial by Stage of Development, 2000–2010
Table 26: Clinical Trial Recruitment in Orphan Diseases, ALS, Average Number of Patients Recruited per Trial per Year, 2000–2010
Table 27: Clinical Trial Recruitment in Orphan Diseases, Comparison of Clinical Trials in Orphan Diseases With Other Diseases in CNS, Global, 2000–2010
Table 28: Clinical Trial Recruitment in Orphan Diseases, Comparison of Patients Recruited in Orphan Diseases With Other Diseases in CNS, Global, 2000–2010
Table 29: Clinical Trial Recruitment in Orphan Diseases, Average Number of Patients Recruited per Phase in Orphan Diseases Compared to Other Diseases in CNS, Global, 2000–2010
Table 30: Clinical Trial Recruitment in Orphan Diseases, Average Number of Patients Recruited per Year in Orphan Diseases Compared to Other Diseases in CNS, Global, 2000–2010
Table 31: Clinical Trial Recruitment in Orphan Diseases, Ovarian Cancer, Total Number of Clinical Trials by Phase, 2000–2010
Table 32: Clinical Trial Recruitment in Orphan Diseases, Ovarian Cancer, Total Number of Clinical Trials by Major Sponsors, 2000–2010
Table 33: Clinical Trial Recruitment in Orphan Diseases, Ovarian Cancer, Total Number of Clinical Trials by Geography, 2000–2010
Table 34: Clinical Trial Recruitment in Orphan Diseases, Ovarian Cancer, Total Number of Clinical Trials by Year, 2000–2010
Table 35: Clinical Trial Recruitment in Orphan Diseases, Ovarian Cancer, The US, Prevalence Population, 2010–2017
Table 36: Clinical Trial Recruitment in Orphan Diseases, Ovarian Cancer, Europe, Prevalence Population, 2010–2017
Table 37: Clinical Trial Recruitment in Orphan Diseases, Ovarian Cancer, Japan, Prevalence Population, 2010–2017
Table 38: Clinical Trial Recruitment in Orphan Diseases, Ovarian Cancer, Total Number of Patients Recruited by Phase, 2000–2010
Table 39: Clinical Trial Recruitment in Orphan Diseases, Ovarian Cancer, Total Number of Patients Recruited by Major Sponsors, 2000–2010
Table 40: Clinical Trial Recruitment in Orphan Diseases, Ovarian Cancer, Total Number of Patients Recruited by Geography, 2000–2010
Table 41: Clinical Trial Recruitment in Orphan Diseases, Ovarian Cancer, Total Number of Patients Recruited per Year, 2000–2010
Table 42: Clinical Trial Recruitment in Orphan Diseases, Ovarian Cancer, Average Number of Patients Recruited per Trial by Stage of Development, 2000–2010
Table 43: Clinical Trial Recruitment in Orphan Diseases, Ovarian Cancer, Average Number of Patients Recruited per Trial per Year, 2000–2010
Table 44: Clinical Trial Recruitment in Orphan Diseases, Pancreatic Cancer, Total Number of Clinical Trials by Phase, 2000–2010
Table 45: Clinical Trial Recruitment in Orphan Diseases, Pancreatic Cancer, Total Number of Clinical Trials by Major Sponsors, 2000–2010
Table 46: Clinical Trial Recruitment in Orphan Diseases, Pancreatic Cancer, Total Number of Clinical Trials by Geography, 2000–2010
Table 47: Clinical Trial Recruitment in Orphan Diseases, Pancreatic Cancer, Total Number of Clinical Trials per Year, 2000–2010
Table 48: Clinical Trial Recruitment in Orphan Diseases, Pancreatic Cancer, The US, Prevalence Population, 2010–2017
Table 49: Clinical Trial Recruitment in Orphan Diseases, Pancreatic Cancer, Europe, Prevalence Population, 2010–2017
Table 50: Clinical Trial Recruitment in Orphan Diseases, Pancreatic Cancer, Japan, Prevalence Population, 2010–2017
Table 51: Clinical Trial Recruitment in Orphan Diseases, Pancreatic Cancer, Total Number of Patients Recruited by Phase, 2000–2010
Table 52: Clinical Trial Recruitment in Orphan Diseases, Pancreatic Cancer, Total Number of Patients Recruited by Major Sponsors, 2000–2010
Table 53: Clinical Trial Recruitment in Orphan Diseases, Pancreatic Cancer, Total Number of Patients Recruited by Geography, 2000–2010
Table 54: Clinical Trial Recruitment in Orphan Diseases, Pancreatic Cancer, Total Number of Patients Recruited per Year, 2000–2010
Table 55: Clinical Trial Recruitment in Orphan Diseases, Pancreatic Cancer, Average Number of Patients Recruited per Trial by Stage of Development, 2000–2010
Table 56: Clinical Trial Recruitment in Orphan Diseases, Pancreatic Cancer, Average Number of Patients Recruited per Trial per Year, 2000–2010
Table 57: Clinical Trial Recruitment in Orphan Diseases, Multiple Myeloma, Total Number of Clinical Trials by Phase, 2000–2010
Table 58: Clinical Trial Recruitment in Orphan Diseases, Multiple Myeloma, Total Number of Clinical Trials by Major Sponsors, 2000–2010
Table 59: Clinical Trial Recruitment in Orphan Diseases, Multiple Myeloma, Total Number of Clinical Trials by Geography, 2000–2010
Table 60: Clinical Trial Recruitment in Orphan Diseases, Multiple Myeloma, Total Number of Clinical Trials per Year, 2000–2010
Table 61: Clinical Trial Recruitment in Orphan Diseases, Multiple Myeloma, The US, Prevalence Population, 2010–2017
Table 62: Clinical Trial Recruitment in Orphan Diseases, Multiple Myeloma, Europe, Prevalence Population, 2010–2017
Table 63: Clinical Trial Recruitment in Orphan Diseases, Multiple Myeloma, Japan, Prevalence Population, 2010–2017
Table 64: Clinical Trial Recruitment in Orphan Diseases, Multiple Myeloma, Total Number of Patients Recruited by Phase, 2000–2010
Table 65: Clinical Trial Recruitment in Orphan Diseases, Multiple Myeloma, Total Number of Patients Recruited by Major Sponsors, 2000–2010
Table 66: Clinical Trial Recruitment in Orphan Diseases, Multiple Myeloma, Total Number of Patients Recruited by Geography, 2000–2010
Table 67: Clinical Trial Recruitment in Orphan Diseases, Multiple Myeloma, Total Number of Patients Recruited per Year, 2000–2010
Table 68: Clinical Trial Recruitment in Orphan Diseases, Multiple Myeloma, Average Number of Patients Recruited per Trial by Stage of Development, 2000–2010
Table 69: Clinical Trial Recruitment in Orphan Diseases, Multiple Myeloma, Average Number of Patients Recruited per Trial per Year, 2000–2010
Table 70: Clinical Trial Recruitment in Orphan Diseases, Hodgkin’s Lymphoma, Total Number of Clinical Trials by Phase, 2000–2010
Table 71: Clinical Trial Recruitment in Orphan Diseases, Hodgkin’s Lymphoma, Total Number of Clinical Trials by Major Sponsors, 2000–2010
Table 72: Clinical Trial Recruitment in Orphan Diseases, Hodgkin’s Lymphoma, Total Number of Clinical Trials by Geography, 2000–2010
Table 73: Clinical Trial Recruitment in Orphan Diseases, Hodgkin’s Lymphoma, Total Number of Clinical Trials per Year, 2000–2010
Table 74: Clinical Trial Recruitment in Orphan Diseases, Hodgkin’s Lymphoma, The US, Prevalence Population, 2010-2017
Table 75: Clinical Trial Recruitment in Orphan Diseases, Hodgkin’s Lymphoma, Europe, Prevalence Population, 2010-2017
Table 76: Clinical Trial Recruitment in Orphan Diseases, Hodgkin’s Lymphoma, Japan, Prevalence Population, 2010-2017
Table 77: Clinical Trial Recruitment in Orphan Diseases, Hodgkin’s Lymphoma, Total Number of Patients Recruited by Phase, 2000–2010
Table 78: Clinical Trial Recruitment in Orphan Diseases, Hodgkin’s Lymphoma, Total Number of Patients Recruited by Major Sponsors, 2000–2010
Table 79: Clinical Trial Recruitment in Orphan Diseases, Hodgkin’s Lymphoma, Total Number of Patients Recruited by Geography, 2000–2010
Table 80: Clinical Trial Recruitment in Orphan Diseases, Hodgkin’s Lymphoma, Total Number of Patients Recruited per Year, 2000–2010
Table 81: Clinical Trial Recruitment in Orphan Diseases, Hodgkin’s Lymphoma, Average Number of Patients Recruited per Trial by Stage of Development, 2000–2009
Table 82: Clinical Trial Recruitment in Orphan Diseases, Hodgkin’s Lymphoma, Average Number of Patients Recruited per Trial per Year, 2000–2010
Table 83: Clinical Trial Recruitment in Orphan Diseases, AML, Total Number of Clinical Trials by Phase, 2000–2010
Table 84: Clinical Trial Recruitment in Orphan Diseases, AML, Total Number of Clinical Trials by Major Sponsors, 2000–2010
Table 85: Clinical Trial Recruitment in Orphan Diseases, AML, Total Number of Clinical Trials by Geography, 2000–2010
Table 86: Clinical Trial Recruitment in Orphan Diseases, AML, Total Number of Clinical Trials per Year, 2000–2010
Table 87: Clinical Trial Recruitment in Orphan Diseases, AML, The US, Prevalence Population, 2010-2017
Table 88: Clinical Trial Recruitment in Orphan Diseases, AML, Europe, Prevalence Population, 2010-2017
Table 89: Clinical Trial Recruitment in Orphan Diseases, AML, Japan, Prevalence Population, 2010-2017
Table 90: Clinical Trial Recruitment in Orphan Diseases, AML, Total Number of Patients Recruited by Phase, 2000–2010
Table 91: Clinical Trial Recruitment in Orphan Diseases, AML, Total Number of Patients Recruited by Major Sponsors, 2000–2010
Table 92: Clinical Trial Recruitment in Orphan Diseases, AML, Total Number of Patients Recruited by Geography, 2000–2010
Table 93: Clinical Trial Recruitment in Orphan Diseases, AML, Total Number of Patients Recruited per Year, 2000–2010
Table 94: Clinical Trial Recruitment in Orphan Diseases, AML, Average Number of Patients Recruited per Trial by Stage of Development, 2000–2010
Table 95: Clinical Trial Recruitment in Orphan Diseases, AML, Average Number of Patients Recruited per Trial per Year, 2000–2010
Table 96: Clinical Trial Recruitment in Orphan Diseases, Clinical Trials in Orphan Diseases Compared To Other Diseases In Oncology, Global, 2000–2010
Table 97: Clinical Trial Recruitment in Orphan Diseases, Total Patients Recruited in Orphan Diseases Compared To Other Diseases In Oncology, Global, 2000–2010
Table 98: Clinical Trial Recruitment in Orphan Diseases, Average Number of Patients Recruited per Phase in Orphan Diseases Compared To Other Diseases In Oncology, Global, 2000–2010
Table 99: Clinical Trial Recruitment in Orphan Diseases, Average Number of Patients Recruited per Year in Orphan Diseases Compared To Other Diseases In Oncology, Global, 2000–2010

1.2 List of Figures

Figure 1: Clinical Trial Recruitment in Orphan Diseases, Huntington’s Disease, Total Number of Clinical Trials by Phase, 2000–2010
Figure 2: Clinical Trial Recruitment in Orphan Diseases, Huntington’s Disease, Total Number of Clinical Trials by Major Sponsors, 2000–2010
Figure 3: Clinical Trial Recruitment in Orphan Diseases, Huntington’s Disease, Total Number of Clinical Trials by Geography, 2000–2010
Figure 4: Clinical Trial Recruitment in Orphan Diseases, Huntington’s Disease, Total Number of Clinical Trials by Year, 2000–2010
Figure 5: Clinical Trial Recruitment in Orphan Diseases, Huntington’s Disease, The US, Prevalence Population, 2010–2017
Figure 6: Clinical Trial Recruitment in Orphan Diseases, Huntington’s Disease, Europe, Prevalence Population, 2010–2017
Figure 7: Clinical Trial Recruitment in Orphan Diseases, Huntington’s Disease, Japan, Prevalence Population, 2010–2017
Figure 8: Clinical Trial Recruitment in Orphan Diseases, Huntington’s Disease, Total Number of Patients Recruited by Phase, 2000–2010
Figure 9: Clinical Trial Recruitment in Orphan Diseases, Huntington’s Disease, Total Number of Patients Recruited by Major Sponsors, 2000–2010
Figure 10: Clinical Trial Recruitment in Orphan Diseases, Huntington’s Disease, Total Number of Patients Recruited by Geography, 2000–2010
Figure 11: Clinical Trial Recruitment in Orphan Diseases, Huntington’s Disease, Total Number of Patients Recruited by Year, 2000–2010
Figure 12: Clinical Trial Recruitment in Orphan Diseases, Huntington’s Disease, Total, Average Number of Patients Recruited per Trial by Stage of Development, 2000–2010
Figure 13: Clinical Trial Recruitment in Orphan Diseases, Huntington’s Disease, Total, Average Number of Patients Recruited per Trial per Year, 2000–2010
Figure 14: Clinical Trial Recruitment in Orphan Diseases, ALS, Total Number of Clinical Trials by Phase, 2000–2010
Figure 15: Clinical Trial Recruitment in Orphan Diseases, ALS, Total Number of Clinical Trials by Sponsor, 2000–2010
Figure 16: Clinical Trial Recruitment in Orphan Diseases, ALS, Total Number of Clinical Trials by Geography, 2000–2010
Figure 17: Clinical Trial Recruitment in Orphan Diseases, ALS, Total Number of Clinical Trials by Year, 2000–2010
Figure 18: Clinical Trial Recruitment in Orphan Diseases, ALS, The US, Prevalence Population, 2010–2017
Figure 19: Clinical Trial Recruitment in Orphan Diseases, ALS, Europe, Prevalence Population, 2010–2017
Figure 20: Clinical Trial Recruitment in Orphan Diseases, ALS, Japan, Prevalence Population, 2010–2017
Figure 21: Clinical Trial Recruitment in Orphan Diseases, ALS, Total Number of Patients Recruited by Phase, 2000–2010
Figure 22: Clinical Trial Recruitment in Orphan Diseases, ALS, Total Number of Patients Recruited by Major Sponsors, 2000–2010
Figure 23: Clinical Trial Recruitment in Orphan Diseases, ALS, Total Number of Patients Recruited by Geography, 2000–2010
Figure 24: Clinical Trial Recruitment in Orphan Diseases, ALS, Total Number of Patients Recruited by Year, 2000–2010
Figure 25: Clinical Trial Recruitment in Orphan Diseases, ALS, Average Number of Patients Recruited per Trial by Stage of Development, 2000–2010
Figure 26: Clinical Trial Recruitment in Orphan Diseases, ALS, Average Number of Patients Recruited per Trial per Year, 2000–2010
Figure 27: Clinical Trial Recruitment in Orphan Diseases, Comparison of Clinical Trials in Orphan Diseases With Other Diseases in CNS, Global, 2000–2010
Figure 28: Clinical Trial Recruitment in Orphan Diseases, Comparison of Patients Recruited in Orphan Diseases With Other Diseases in CNS, Global, 2000–2010
Figure 29: Clinical Trial Recruitment in Orphan Diseases, Average Number of Patients Recruited per Phase in Orphan Diseases Compared to Other Diseases in CNS, Global, 2000–2010
Figure 30: Clinical Trial Recruitment in Orphan Diseases, Average Number of Patients Recruited per Year in Orphan Diseases Compared to Other Diseases in CNS, Global, 2000–2010
Figure 31: Clinical Trial Recruitment in Orphan Diseases, Ovarian Cancer, Total Number of Patients Recruited by Phase, 2000–2010
Figure 32: Clinical Trial Recruitment in Orphan Diseases, Ovarian Cancer, Total Number of Clinical Trials by Major Sponsors, 2000–2010
Figure 33: Clinical Trial Recruitment in Orphan Diseases, Ovarian Cancer, Total Number of Clinical Trials by Geography, 2000–2010
Figure 34: Clinical Trial Recruitment in Orphan Diseases, Ovarian Cancer, Total Number of Clinical Trials by Year, 2000–2010
Figure 35: Clinical Trial Recruitment in Orphan Diseases, Ovarian Cancer, The US, Prevalence Population, 2010–2017
Figure 36: Clinical Trial Recruitment in Orphan Diseases, Ovarian Cancer, Europe, Prevalence Population, 2010–2017
Figure 37: Clinical Trial Recruitment in Orphan Diseases, Ovarian Cancer, Japan, Prevalence Population, 2010–2017
Figure 38: Clinical Trial Recruitment in Orphan Diseases, Ovarian Cancer, Total Number of Patients Recruited by Phase, 2000–2010
Figure 39: Clinical Trial Recruitment in Orphan Diseases, Ovarian Cancer, Total Number of Patients Recruited by Major Sponsors, 2000–2010
Figure 40: Clinical Trial Recruitment in Orphan Diseases, Ovarian Cancer, Total Number of Patients Recruited by Geography, 2000–2010
Figure 41: Clinical Trial Recruitment in Orphan Diseases, Ovarian Cancer, Total Number of Patients Recruited per Year, 2000–2010
Figure 42: Clinical Trial Recruitment in Orphan Diseases, Ovarian Cancer, Average Number of Patients Recruited per Trial by Stage of Development, 2000–2010
Figure 43: Clinical Trial Recruitment in Orphan Diseases, Ovarian Cancer, Average Number of Patients Recruited per Trial per Year, 2000–2010
Figure 44: Clinical Trial Recruitment in Orphan Diseases, Pancreatic Cancer, Total Number of Clinical Trials by Phase, 2000–2010
Figure 45: Clinical Trial Recruitment in Orphan Diseases, Pancreatic Cancer, Total Number of Clinical Trials by Major Sponsors, 2000–2010
Figure 46: Clinical Trial Recruitment in Orphan Diseases, Pancreatic Cancer, Total Number of Clinical Trials by Geography, 2000–2010
Figure 47: Clinical Trial Recruitment in Orphan Diseases, Pancreatic Cancer, Total Number of Clinical Trials per Year, 2000–2010
Figure 48: Clinical Trial Recruitment in Orphan Diseases, Pancreatic Cancer, The US, Prevalence Population, 2010–2017
Figure 49: Clinical Trial Recruitment in Orphan Diseases, Pancreatic Cancer, Europe, Prevalence Population, 2010–2017
Figure 50: Clinical Trial Recruitment in Orphan Diseases, Pancreatic Cancer, Japan, Prevalence Population, 2010–2017
Figure 51: Clinical Trial Recruitment in Orphan Diseases, Pancreatic Cancer, Total Number of Patients Recruited by Phase, 2000–2010
Figure 52: Clinical Trial Recruitment in Orphan Diseases, Pancreatic Cancer, Total Number of Patients Recruited by Major Sponsors, 2000–2010
Figure 53: Clinical Trial Recruitment in Orphan Diseases, Pancreatic Cancer, Total Number of Patients Recruited by Geography, 2000–2010
Figure 54: Clinical Trial Recruitment in Orphan Diseases, Pancreatic Cancer, Total Number of Patients Recruited per Year, 2000–2010
Figure 55: Clinical Trial Recruitment in Orphan Diseases, Pancreatic Cancer, Average Number of Patients Recruited per Trial by Stage of Development, 2000–2010
Figure 56: Clinical Trial Recruitment in Orphan Diseases, Pancreatic Cancer, Average Number of Patients Recruited per Trial per Year, 2000–2010
Figure 57: Clinical Trial Recruitment in Orphan Diseases, Multiple Myeloma, Total Number of Clinical Trials by Phase, 2000–2010
Figure 58: Clinical Trial Recruitment in Orphan Diseases, Multiple Myeloma, Total Number of Clinical Trials by Major Sponsors, 2000–2010
Figure 59: Clinical Trial Recruitment in Orphan Diseases, Multiple Myeloma, Total Number of Clinical Trials by Geography, 2000–2010
Figure 60: Clinical Trial Recruitment in Orphan Diseases, Multiple Myeloma, Total Number of Clinical Trials per Year, 2000–2010
Figure 61: Clinical Trial Recruitment in Orphan Diseases, Multiple Myeloma, The US, Prevalence Population, 2010–2017
Figure 62: Clinical Trial Recruitment in Orphan Diseases, Multiple Myeloma, Europe, Prevalence Population, 2010–2017
Figure 63: Clinical Trial Recruitment in Orphan Diseases, Multiple Myeloma, Japan, Prevalence Population, 2010–2017
Figure 64: Clinical Trial Recruitment in Orphan Diseases, Multiple Myeloma, Total Number of Patients Recruited by Phase, 2000–2010
Figure 65: Clinical Trial Recruitment in Orphan Diseases, Multiple Myeloma, Total Number of Patients Recruited by Major Sponsors, 2000–2010
Figure 66: Clinical Trial Recruitment in Orphan Diseases, Multiple Myeloma, Total Number of Patients Recruited by Geography, 2000–2010
Figure 67: Clinical Trial Recruitment in Orphan Diseases, Multiple Myeloma, Total Number of Patients Recruited per Year, 2000–2010
Figure 68: Clinical Trial Recruitment in Orphan Diseases, Multiple Myeloma, Average Number of Patients Recruited per Trial by Stage of Development, 2000–2010
Figure 69: Clinical Trial Recruitment in Orphan Diseases, Multiple Myeloma, Average Number of Patients Recruited per Trial per Year, 2000–2010
Figure 70: Clinical Trial Recruitment in Orphan Diseases, Hodgkin’s Lymphoma, Total Number of Clinical Trials by Phase, 2000–2010
Figure 71: Clinical Trial Recruitment in Orphan Diseases, Hodgkin’s Lymphoma, Total Number of Clinical Trials by Major Sponsors, 2000–2010
Figure 72: Clinical Trial Recruitment in Orphan Diseases, Hodgkin’s Lymphoma, Total Number of Clinical Trials by Geography, 2000–2010
Figure 73: Clinical Trial Recruitment in Orphan Diseases, Hodgkin’s Lymphoma, Total Number of Clinical Trials per Year, 2000–2010
Figure 74: Clinical Trial Recruitment in Orphan Diseases, Hodgkin’s Lymphoma, The US, Prevalence Population, 2010-2017
Figure 75: Clinical Trial Recruitment in Orphan Diseases, Hodgkin’s Lymphoma, Europe, Prevalence Population, 2010-2017
Figure 76: Clinical Trial Recruitment in Orphan Diseases, Hodgkin’s Lymphoma, Japan, Prevalence Population, 2010-2017
Figure 77: Clinical Trial Recruitment in Orphan Diseases, Hodgkin’s Lymphoma, Total Number of Patients Recruited by Phase, 2000–2010
Figure 78: Clinical Trial Recruitment in Orphan Diseases, Hodgkin’s Lymphoma, Total Number of Patients Recruited by Major Sponsors, 2000–2010
Figure 79: Clinical Trial Recruitment in Orphan Diseases, Hodgkin’s Lymphoma, Total Number of Patients Recruited by Geography, 2000–2010
Figure 80: Clinical Trial Recruitment in Orphan Diseases, Hodgkin’s Lymphoma, Total Number of Patients Recruited per Year, 2000–2010
Figure 81: Clinical Trial Recruitment in Orphan Diseases, Hodgkin’s Lymphoma, Average Number of Patients Recruited per Trial by Stage of Development, 2000–2009
Figure 82: Clinical Trial Recruitment in Orphan Diseases, Hodgkin’s Lymphoma, Average Number of Patients Recruited per Trial per Year, 2000–2010
Figure 83: Clinical Trial Recruitment in Orphan Diseases, AML, Total Number of Clinical Trials by Phase, 2000–2010
Figure 84: Clinical Trial Recruitment in Orphan Diseases, AML, Total Number of Clinical Trials by Major Sponsors, 2000–2010
Figure 85: Clinical Trial Recruitment in Orphan Diseases, AML, Total Number of Clinical Trials by Geography, 2000–2010
Figure 86: Clinical Trial Recruitment in Orphan Diseases, AML, Total Number of Clinical Trials per Year, 2000–2010
Figure 87: Clinical Trial Recruitment in Orphan Diseases, AML, The US, Prevalence Population, 2010-2017
Figure 88: Clinical Trial Recruitment in Orphan Diseases, AML, Europe, Prevalence Population, 2010-2017
Figure 89: Clinical Trial Recruitment in Orphan Diseases, AML, Japan, Prevalence Population, 2010-2017
Figure 90: Clinical Trial Recruitment in Orphan Diseases, AML, Total Number of Patients Recruited by Phase, 2000–2010
Figure 91: Clinical Trial Recruitment in Orphan Diseases, AML, Total Number of Patients Recruited by Major Sponsors, 2000–2010
Figure 92: Clinical Trial Recruitment in Orphan Diseases, AML, Total Number of Patients Recruited by Geography, 2000–2010
Figure 93: Clinical Trial Recruitment in Orphan Diseases, AML, Total Number of Patients Recruited per Year, 2000–2010
Figure 94: Clinical Trial Recruitment in Orphan Diseases, AML, Average Number of Patients Recruited per Trial by Stage of Development, 2000–2010
Figure 95: Clinical Trial Recruitment in Orphan Diseases, AML, Average Number of Patients Recruited per Trial per Year, 2000–2010
Figure 96: Clinical Trial Recruitment in Orphan Diseases, Clinical Trials in Orphan Diseases Compared To Other Diseases In Oncology, Global, 2000–2010
Figure 97: Clinical Trial Recruitment in Orphan Diseases, Total Patients Recruited in Orphan Diseases Compared To Other Diseases In Oncology, Global, 2000–2010
Figure 98:Clinical Trial Recruitment in Orphan Diseases, Average Number of Patients Recruited per Phase in Orphan Diseases Compared To Other Diseases In Oncology, Global, 2000–2010
Figure 99:Clinical Trial Recruitment in Orphan Diseases, Average Number of Patients Recruited per Year in Orphan Diseases Compared To Other Diseases In Oncology, Global, 2000–2010

GBI Research, the leading business intelligence provider, has released its latest research, “Clinical Trial Recruitment in Orphan Diseases - Patient Numbers in Ovarian Cancer Trials Exceed Other Orphan Diseases in Oncology”. It gives a robust idea about the patient recruitment status by geography, by Sponsor Company and by year for all the major orphan diseases in CNS and oncology. The report also compares the clinical trials and patient recruitment in orphan diseases with other diseases in CNS and oncology. Furthermore, the report provides profiles of prevalence forecast data up to 2017 for all the major indications. The major indications covered in the report are Huntington’s disease, Amyotrophic Lateral Sclerosis (ALS), ovarian disease, pancreatic disease, Hodgkin’s lymphoma, multiple myeloma and Acute Myeloid Leukemia (AML). It is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts.

Orphan Diseases in Central Nervous System (CNS) Has Lesser Number of Clinical Trials As Compared To Other CNS Diseases

GBI Research compared the number of clinical trials conducted in orphan diseases in CNS along with the most common CNS disorders. The number of clinical trials in orphan disease between 2000 and 2010 accounts for lesser number of clinical trials than other diseases such as Alzheimer’s disease, Parkinson’s disease, Epilepsy, Schizophrenia and Depression. The number of clinical trials conducted in Alzheimer’s disease, Parkinson’s disease, Epilepsy, Schizophrenia and Depression was 201, 129, 114, 273 and 131 respectively whereas Huntington’s disease and Amyotrophic Lateral Sclerosis (AML) accounts for 15 and 16 trials respectively.

The Average Number of Patients Recruited per Clinical Trial Was Lower For Orphan Diseases in Oncology As Compared To Breast Cancer

Clinical Trial Recruitment in Orphan Diseases, Average Number of Patients Recruited per Phase in Orphan Diseases Compared To Other Diseases In Oncology, Global, 2000¬–2010

The average number of patients recruited per trial in orphan diseases in oncology was lower than the other oncology diseases such as breast cancer. In breast cancer trials, on average 1,041 patients were recruited per clinical trial in Phase III, whereas trials for orphan diseases in oncology recruited 517, 251, 425, 288 and 429 patients in trials for ovarian cancer, Hodgkin’s lymphoma, multiple myeloma, AML and pancreatic cancer.

Order Online - visit http://www.researchandmarkets.com/reports/1582661

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.